Study high­lights the FDA’s speed in ap­prov­ing can­cer drugs as a new com­mish looks to rev up re­views

Dur­ing his con­fir­ma­tion hear­ing on Wednes­day Scott Got­tlieb em­pha­sized that he would start his new job as FDA com­mis­sion­er by fo­cus­ing on dif­fer­ent parts of the agency that have lagged in ac­cel­er­at­ing drug re­views. With the pres­i­dent beat­ing the ta­ble for a stream­lined ap­proval process, you can ex­pect some fresh pres­sure from the top to speed things up. And now Got­tlieb — who was al­ready on record on that score — has some ad­di­tion­al da­ta to point to for his ef­fi­cien­cy cam­paign, high­light­ing where the agency has been ef­fec­tive in speed­ing ap­provals and where it might push for faster ac­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER